Blauvelt A, Sofen H, Papp K, et al. - In patients with different levels of week-28 Psoriasis Area and Severity Index (PASI) improvement, researchers conducted this pooled post hoc analysis to test the effectiveness of tildrakizumab and its effect on the quality of life (QoL). ReSURFACE 1 and reSURFACE 2 pooled patients treated with 100 mg or 200 mg tildrakizumab from baseline to week 28 and classified into five mutually exclusive week-28 PASI improvement groups for each dose: PASI 0–49, 50–74, 75–89, 90–99 and 100. A total of 1,156 patients from the two trials were pooled. Of these patients, 575 (mean age was 45.6 years) were in the 100-mg and 578 (mean age was 45.9 years) in the 200-mg cohorts, respectively. Investigators found that patients who are unlikely to respond to tildrakizumab could be identified by week 8, and those who are likely to respond to PASI ≥ 90 could be identified at week 4. Week-28 level of PASI improvement correlated with improvement in QoL. These findings are essential because they indicate that patients and their health care providers can make a well-educated choice on whether or not to continue tildrakizumab treatment by week 12 or 16 (ie, prior to the third dose).